McCormick & Company, Incorporated (MKC) Stock Price Today
Key Stats
- $14.24BMarket Cap
- -Volume
- Consumer StaplesSector
- $72.2652W High
- $45.6052W Low
- -Typical Hold Time
- $18.84BEnterprise Value
- 3.62%Div Yield
- -Trading Activity
Track McCormick & Company, Incorporated (MKC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, McCormick & Company, Incorporated has traded between a low of $45.6 and a high of $72.26, highlighting its annual price range. Buy and sell McCormick & Company, Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Most Recent News
Goldman Sachs downgrades AMD to Sell despite record Q2 revenue and AI growth.
Goldman Sachs downgraded Advanced Micro Devices (AMD) to a Sell rating despite the company reporting record Q2 revenue of $11.54 billion, driven largely by its Data Center segment which accounts for 58% of sales. AMD projects strong Q3 revenue of $13...
Stocks fall sharply amid fraud probe and mixed earnings, with Cellebrite down 29%.
Several stocks dropped significantly today due to various company-specific issues. Cellebrite DI Ltd. plunged 29.18% following a securities fraud investigation, while Securitize Corp. fell 27.48% despite a major NYSE listing milestone. Liftoff Mobile...
Altimmune CEO buys shares, signaling confidence amid strong Q2 results and MASH drug progress.
Altimmune's CEO recently purchased 15,000 shares at $2.95 each, showing strong leadership confidence in the company's future. The biopharmaceutical firm reported a better-than-expected Q2 loss of $0.12 per share and holds $519 million in cash, securi...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.